{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Endocrine AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Gastrointestinal AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Hepatic AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Pulmonary AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Renal AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Skin AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Hypersensitivity/Infusion Reaction AEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"}],"units":"Participants"}],"description":"Number of participants with any grade of drug-related select adverse events (AEs) including endocrine, gastrointestinal, hepatic, pulmonary, renal, skin, and hypersensitivity AEs in Neoadjuvant cohort","groups":[{"description":"Nivolumab administered intravenously (IV) over 30 minutes at 240 mg for 2 doses, on Day 1 and Day 15","id":"OG000","title":"Neoadjuvant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in the neoadjuvant cohort","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days post last dose (Up to 2 months)","title":"Neoadjuvant: Number of Participants With Drug-Related Select Adverse Events (AEs)","type":"PRIMARY","unitOfMeasure":"Participants"}